While the SCHOLAR [103] and SAFE-Heart [104••, 105] studies addressed congestive HF that occurred with anthracycline/anti-HER2 treatments as opposed to preexisting HF, they were able to show that most of their cohorts could be medically managed with medical therapy to continue and complete their breast cancer treatments. This evidence concerns the gene ERBB2 and breast cancer.